The LeaderMed team’s expertise allows them to advance and obtain regulatory approvals for new drugs in China and the Asia-Pacific region faster than what can be secured in the U.S. and Europe.
In the China and Asia-Pacific markets our team members have led over 60 trials for innovative drugs; co-founded a CRO; led over 10 successful NDAs; and commercialized over $3 billion in global drug sales and medical devices, benefitting patients in over 50 countries.